Percutaneous Direct Annuloplasty: Lessons From an Early Feasibility Trial

[...]improvement in symptoms is very difficult to prove because of their subjective nature. [...]because double-blind assessment is almost impossible and there is potential for a placebo effect, symptom improvement by itself cannot be used as a sole reliable endpoint.\n What is a Safe Procedure? [...]preserving future options for treatment is another important "safety" feature, and it appears that the Mitralign technology may fulfill this criterion, as 7 patients in the treated group underwent subsequent MitraClip (Abbott Vascular, Santa Clara, California) placement and 1 underwent MV surgery.